Pancreatic Cancer Clinical Trial
Official title:
Pancreaticoduodenectomy: Outcomes of a Complex Surgical Procedure From a Developing Country
| Verified date | May 2020 |
| Source | Shaukat Khanum Memorial Cancer Hospital & Research Centre |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
ABSTRACT
BACKGROUND Pancreaticoduodenectomy (PD) plays an integral part in the management of
pancreatic, periampullary and duodenal cancers along with few other pathologies of this
region. Despite advances in surgery PD continues to have significant morbidity and noteworthy
mortality. The aim of this study is to provide an in-depth report on the patient
characteristics, indications and the outcomes of PD) in a tertiary cancer hospital in
Pakistan.
MATERIALS AND METHODS:
The study population included patients who underwent PD between January 1st 2014 and march
31st 2019, at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in
Pakistan. The Data was retrospectively analyzed from the Hospital Information System (HIS),
which is a prospectively maintained patient electronic database of SKMCH&RC. Patient
characteristics, procedural details and post-operative outcomes according to internationally
accepted definitions were reported.
KEYWORDS: Whipple's procedure, Pancreaticoduodenectomy, Pancreaticogastrostomy, lower middle
income, pancreatic fistula, periampullary cancer.
| Status | Completed |
| Enrollment | 161 |
| Est. completion date | March 15, 2020 |
| Est. primary completion date | March 4, 2020 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 19 Years to 78 Years |
| Eligibility |
Inclusion Criteria: all patients whose surgeries were done from January 2014 to March 2019 Exclusion Criteria: None as such |
| Country | Name | City | State |
|---|---|---|---|
| Pakistan | Shaukat Khanam Memorial Cancer Hospital and Research Center | Lahore | Punjab |
| Lead Sponsor | Collaborator |
|---|---|
| Shaukat Khanum Memorial Cancer Hospital & Research Centre |
Pakistan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Survival analysis | disease free and overall survival | 4 years | |
| Secondary | Morbidity | morbidity was defined according to Clavien-Dindo classification | 30 days | |
| Secondary | recurrence | recurrence is defined as return of the cancer after initial curative or definitive treatment, can be local or distant | 4 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|